By SPC News Staff
The FDA issued a warning about the risk for anaphylaxis, which could lead to hospitalizations and deaths, with the medicine glatiramer acetate (Copaxone, Teva; Glatopa, Sandoz) used to treat patients with multiple sclerosis (MS).
The agency ordered a new boxed warning about the risk to the glatiramer acetate prescribing information afteridentifying 82 worldwide cases of anaphylaxis and six deaths associated with the drug occurring from December 1996 through May